Barbara Walters to headline 2014 NACDS Foundation Dinner
ARLINGTON, Va. — Renowned news correspondent, host and producer Barbara Walters will serve as the keynote speaker for the National Association of Chain Drug Stores Foundation Dinner, which will be held on Dec. 3 in New York City.
In its 16th year, the NACDS Foundation Dinner and contributions from the Foundation’s benefactors help support evidence-based research that advances patient care, pharmacy education, student scholarships, and charitable organizations that improve patient outcomes.
“Throughout her career, Barbara Walters has given viewers new perspectives on the fascinating leaders and luminaries she has interviewed,” stated NACDS Foundation president Kathleen Jaeger. “Her ability to bring a truly personal approach to the news helped her to emerge as one of the most highly-respected journalists in television history. We are deeply honored that Ms. Walters will serve as the keynote speaker for the NACDS Foundation Dinner this year.”
A native of Boston, Mass., Walters’ television career spans more than five decades. Known for her exclusive interviews with world leaders, primetime specials and daytime television, Walters has interviewed every American President and First Lady since Richard Nixon. Walters made news history by arranging the first joint interview with Egypt’s President Anwar Sadat and Israel’s Prime Minister Menachem Begin in November 1977. Another of her “firsts” was an hour-long primetime conversation with Cuban President Fidel Castro — an interview which has been printed in half a dozen languages and broadcast all over the world.
Walters appeared on NBC’s “Today Show” for 15 years. She began as a writer on the “Today Show,” and within a year became a reporter-at-large, developing, writing and editing her own reports and interviews. In 1963 she became a co-host of the program without the official title, but in 1974 NBC officially designated her as the program’s first female co-host. During this time, Walters was a member of the NBC News team that went to the People’s Republic of China to cover the visits of President Richard Nixon in 1972 and President Gerald Ford in 1975.
In 1976, Walters joined ABC News as the first woman to co-host the network news. Likely most well-known for her career with the ABC network, Walters served as co-host and chief correspondent of ABC News’ “20/20” for 25 years, and today is creator, co-owner, executive producer and co-host of the network’s “The View.”
Walters is also known for her primetime specials, including “The Barbara Walters Specials,” which are still top-rated specials and have included such legends as Sir Laurence Olivier, Bing Crosby, John Wayne, Bette Davis, Audrey Hepburn, as well as celebrities such as Betty White, David and Victoria Beckham, and George Clooney.
Through the years she has interviewed such world figures as Russia’s Boris Yeltsin, Chinese Premier Jiang Zemin, Great Britain’s former Prime Minister Margaret Thatcher, Libya’s Moammar Qadaffi and Iraq’s President Sadaam Hussein. She was also the first American journalist to interview Russia’s President Vladimir Putin, and she conducted the first interview with President George W. Bush and the First Lady following the attacks of Sept. 11, 2001.
Walters has received countless awards, distinctions and accolades, including Induction into the Academy of Television Arts and Sciences’ Hall of Fame in 1990 “for being acknowledged worldwide as one of television’s most respected interviewers and journalists;” the 2009 Daytime Emmy Award for “Outstanding Talk Show Host” for the View; and receiving a star on the Hollywood Walk of Fame. Walters is also a New York Times best-selling author for her very personal and revealing memoir “Audition,” released in 2008.
Apothecary names industry vets to three key roles
BURNSVILLE, Minn. — Apothecary Products, a manufacturer and distributor of consumer healthcare products and pharmacy supplies, announced three new hires for its leadership team: Nathan Hanson, president and CEO; Darran Spence, CFO; and Jim O’Sullivan, SVP of sales. All three individuals bring extensive, results-driven experience to their new roles, the company said.
Hanson joins Apothecary from Oasis Brands, where he served as CEO and as a board member. During his tenure, Oasis experienced significant business growth and profitability improvements. Hanson's experience prior to Oasis includes leadership positions with Pure Fishing and Kimberly-Clark.
“I’m honored to join the Apothecary team, and I look forward to working with Jim, Darran, our management team, and our talented employees to continue building upon its success. Apothecary has built a solid reputation, long-term customer relationships, category leadership, and solid financial performance over the years," Hanson said. "I am confident that with the talent we are bringing in coupled with the already strong team that we will be able to create value added innovation that drives growth for our customers and helps consumers live life a little easier and better.”
Before joining Apothecary, Darran Spence was a consultant with River Rock Partners in various capacities: she helped lead acquisition integrations, strategic planning initiatives, and growth strategies for improving overall profitability at businesses. Additionally, Spence provided interim CFO support.
Jim O’Sullivan joins the company from Designer Protein, where he was SVP of sales. During his time at Designer Protein, he led the sales team and also established the organization, systems and processes need to bolster growth.
“Both Darran and Jim bring significant consumer product industry experience and have demonstrated over the course of their respective careers their individual ability to lead growth and profitability improvement, provide leadership, and develop people. On behalf of the entire Apothecary team, we are all excited to have them on board. I am confident that the addition of these two individuals to a strong leadership team and our committed, passionate employees position us for future success and growth,” Hanson added.
FDA expands approval for Lumizyme
SILVER SPRING, Md. — The Food and Drug Administration approved Lumizyme (alglucosidase alfa) for treatment of patients with infantile-onset Pompe disease, including patients who are younger than 8 years of age, the agency said. Additionally, the FDA announced that the risk evaluation and mitigation strategy that is referred to as the Lumizyme ACE program is being discontinued.
Pompe disease is a rare genetic disorder that occurs in an estimated 1-in-every-40,000 to -300,000 births. Heart and skeletal muscle weakness is the primary symptom, which progresses to respiratory weakness and death from respiratory failure.
When Lumizyme was approved in 2010, there wasn't sufficient data to support the drug's safety and efficacy in the infantile-onset Pompe population, so the drug was only approved for use in late onset Pompe disease patients who are at least 8 years of age. The FDA's expanded approval provides access to the drug for all patients with Pompe disease, regardless of age. Lumizyme is manufactured by Genzyme Corp.